Prophylactic cardioverter defibrillator utilization in the "real world": a conundrum

Area of Science:

• Cardiology
• Medical Device Technology
• Clinical Practice Guidelines

Background:

• Randomized controlled trials demonstrate that implantable cardioverter defibrillator (ICD) therapy enhances survival in selected patients with left ventricular dysfunction post-myocardial infarction (MI).
• Consensus guidelines provide specific recommendations for prophylactic ICD therapy in high-risk individuals.
• There is a need to evaluate the adherence to these guidelines in routine clinical practice.

Discussion:

• A tertiary care center report from Israel (2005-2009) revealed that only 14% of indicated post-MI patients received a prophylactic ICD.
• Systematic reassessment of left ventricular function after MI was identified as a critical factor linked to the underuse of ICDs.
• Factors influencing underuse include insurance coverage, patient preferences, physician assessment of comorbidities and age, and limited referrals to specialized centers.

Key Insights:

• Significant underutilization of guideline-indicated prophylactic ICD therapy in post-MI patients observed in real-world practice.
• Failure to systematically reassess left ventricular function is a key driver of this underuse.
• Multiple systemic and patient-specific factors contribute to the gap between recommended and actual ICD implantation rates.

Outlook:

• The discrepancy between recommended and actual ICD implant rates necessitates improved healthcare system integration.
• Further research is needed to identify and implement strategies to bridge the gap between clinical guidelines and real-world application of ICD therapy.
• Enhanced patient and physician education, streamlined referral pathways, and policy adjustments may improve access to life-saving ICD therapy.